Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Vaxil Bio Ltd VXLLF


Primary Symbol: V.VXL

Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19... see more

TSXV:VXL - Post Discussion

Vaxil Bio Ltd > VXL .... and I thought Timothy Leary was dead but....
View:
Post by Iseneschal on Nov 11, 2021 11:40am

VXL .... and I thought Timothy Leary was dead but....

obviously.....his research is still being practiced.
I wonder when they will do something with his cryogeniced head and attach it to another body?

timothy leary quotes - Bing

Vaxil Bio cancels acquisition of Short Wave Pharma

2021-11-11 08:29 ET - News Release

Mr. Gadi Levin reports

VAXIL PROVIDES UPDATE ON ACQUISITION OF SHORT WAVE PHARMA INC.

Further to its press release from Oct. 14, 2021, Vaxil Bio Ltd., together with Short Wave Pharma Inc., has agreed not to pursue Vaxil's acquisition of Short Wave. The decision was reached by both entities following a due diligence process, concluding that the transaction does not deliver sufficient synergies for the two parties.

The parties believe that value can be created by meeting the medical needs of patients suffering from mental health, neurodegenerative and chronic conditions through the use of psychedelics, but the combination of Vaxil and Short Wave is not the optimal platform to achieve these scientific goals.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities